Hongbo Lu

Hongbo Lu

Signal active

Managing Partner

Bio

Hongbo Lu is an Executive Director on the Asia team. Previously, Hongbo Lu spent more than five years at Piper Jaffray & Co as an equity analyst. She led Piper's China healthcare research team and was instrumental in building the firm's brand in the Asian marketplace. Prior to her Wall Street career, Hongbo Lu spent four years in life science start-up operations and business development at Zyomyx, Inc.

Hongbo Lu received a Ph.D. in BioEngineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and a B.S./M.S. in Materials Science and Engineering from Tsinghua University in China.

Location

Palo Alto, California, United States, North America

Social

Primary Organization

Vivo Capital

Vivo Capital

Founded

1996

Investment

216

Lead investment

60

Exits

103

Employees

51-100

Industry

Financial Services, Venture Capital, Finance, Health Care

Jobs history

5

Rgenta Therapeutics

Board Member

Invalid date - Current

Zenas BioPharma

Board Member

2022 - Current

Visirna Therapeutics

Board Member

Invalid date - Current

Ablaze Pharmaceuticals

Board Member

Invalid date - Current

Vivo Capital

Managing Partner

2020 - Current

Board and Advisor Roles

0

N/A

Invest in regions

Profile Resume

Hongbo Lu is the Managing Partner at Vivo Capital, based in United States, North America. With a background in Financial Services, Hongbo Lu has a rich history of leadership and innovation. Hongbo Lu studied Ph.D Bioengineering @ University of Washington. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.

Recommendation from your interest

N/A

Investment portfolio

N/A

Number of investment

1

Number of exits

0

Personal investment

0

There is no personal investment available on this profile

Partner investment

10

Annouced DateOrganization NameFunding RoundInvestor NameMoney Raised
Apr 25, 2022
Visirna Therapeutics Visirna Therapeutics
Seed Round - Visirna Therapeutics
Visirna Therapeutics Vivo Capital
60.0M
Nov 07, 2022
Zenas BioPharma Zenas BioPharma
Series B - Zenas BioPharma
Zenas BioPharma Vivo Capital
118.0M
Nov 29, 2022
Rgenta Therapeutics Rgenta Therapeutics
Series A - Rgenta Therapeutics
Rgenta Therapeutics Vivo Capital
52.0M
Aug 30, 2023
Ronovo Surgical Ronovo Surgical
Series B - Ronovo Surgical
Ronovo Surgical Vivo Capital
27.5M

Exits

0

There is no exit available on this Profile

Invest in industries

Recent Activity

There is no recent news or activity for this profile.